Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Transcept Pharmaceuticals Presents Data From Studies Of Two Product Candidates At Annual Meeting Of The American Psychiatric Association
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today the presentation of two posters at the 2009 annual meeting of the American Psychiatric Association in San Francisco, California.

What Is Typhoid Fever? What Is Typhoid?
Typhoid fever is an infectious disease caused by the bacteria Salmonella typhi. It is also known as enteric fever, or commonly just typhoid. Typhoid fever and paratyphoid fever are clinically indistinguishable diseases, collectively called enteric fever. It easily spreads through contaminated food and water supplies and close contact with others who are infected. The illness is characterized by very high fever, sweating, gastroenteritis, and diarrhea. Although typhoid is very rare in the developed world, it is still a serious health threat in the developing world. Typhoid is treatable with antibiotics.
News of the day
New Delhi: AHF India Cares Launches 'LOVE Condom' Campaign
AIDS Healthcare Foundation (AHF) is launching its "LOVE Condom" campaign with an event today in the New Delhi region on the 18th of July, 2009. The campaign includes the distribution of free AHF "LOVE"-brand condoms, as well as a "Stay Negative" public service advertising campaign. Bollywood actor Ronit Roy will be the chief guest at today"s launch event. The event will be at Metropolitan Hotel Nikko, New Delhi. This campaign will be a new start of HIV AIDS education in India.
Mental Health

St. Jude Medical Applauds MADIT-CRT Trial

St. Jude Medical, Inc. (NYSE: STJ) commends the efforts of investigators in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). The early results of the trial indicate that early intervention with CRT-D therapy can slow a patient"s progression from early stage heart failure (NYHA Class I-II) to late stage heart failure (NYHA Class III-IV). The trial, led by Arthur J. Moss, M.D., principal investigator and Professor of Medicine at the University of Rochester Medical Center, demonstrated cardiac resynchronization therapy is associated with a significant 29 percent reduction (p=0.003) in death or heart failure interventions when compared to traditional implantable cardioverter defibrillator (ICD) therapy in high risk, asymptomatic or mildly symptomatic, New York Heart Association (NYHA) Class I and II patients. About 5 million Americans suffer from heart failure, with 550,000 new cases diagnosed every year, according to the American Heart Association. Currently, patients are typically only given a CRT-D after they have reached NYHA class III or IV heart failure, a much more serious condition. Expanded indications for CRT-D devices based on the MADIT-CRT data would improve the health of many patients in earlier stages of heart failure (NYHA class I and II) by allowing them to receive a CRT-D device. "The MADIT-CRT trial has shown that if intervention is conducted early enough, the outcome for the patient will be better over time," said Mark Carlson, M.D., chief medical officer of the Cardiac Rhythm Management Division of St. Jude Medical. "The next step for our industry is to ensure physicians and patients are aware of the clinically proven effectiveness of this treatment and that they benefit from the currently available cardiac resynchronization therapies." Cardiac resynchronization therapy is used to treat the symptoms and complications associated with certain types of heart failure (HF). CRT is administered using a pacemaker, called a CRT-P, or an ICD with pacing capabilities, called a CRT-D. A CRT-D has the added ability to defibrillate the heart if a patient is at risk for life-threatening arrhythmias. CRT stimulates both of the heart"s lower chambers so that they are "synchronized" and more efficient in pumping blood to the body. The stimulation takes place via a pulse generator (the ICD or pacemaker) and pacing leads, which are placed next to the heart"s tissue and deliver electrical impulses to the heart. St. Jude Medical


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009